LAIR2
Leukocyte-associated immunoglobulin-like receptor 2
Also known as: CD306, LAIR-2, LAIR2_HUMAN
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- Q6ISS4
- Gene
- LAIR2
- Ensembl
- ENSG00000167618
- Chromosome
- 19
- Canonical length
- 152 aa
- Protein class
- CD markers, Predicted intracellular proteins, Predicted secreted proteins
- Secretome location
- Secreted to blood
OverviewNCBI Gene
The protein encoded by this gene is a member of the immunoglobulin superfamily. It was identified by its similarity to leukocyte-associated immunoglobulin-like receptor 1, a membrane-bound receptor that modulates innate immune response. The protein encoded by this locus is a soluble receptor that may play roles in both inhibition of collagen-induced platelet aggregation and vessel formation during placental implantation. This gene maps to a region of 19q13.4, termed the leukocyte receptor cluster, which contains 29 genes in the immunoglobulin superfamily. Alternatively spliced transcript variants have been described for this gene. [provided by RefSeq, Sep 2013]
Canonical amino-acid sequenceUniProt
152 residues, UniProt reviewed canonical sequence.
>Q6ISS4|LAIR2
1 MSPHLTALLG LVLCLAQTIH TQEGALPRPS ISAEPGTVIS PGSHVTFMCR GPVGVQTFRL
61 EREDRAKYKD SYNVFRLGPS ESEARFHIDS VSEGNAGLYR CLYYKPPGWS EHSDFLELLV
121 KESSGGPDSP DTEPGSSAGT VPGTEASGFD APLocalizationUniProt · AlphaFold · HPA
Whether an antibody against LAIR2 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Secreted
- Secreted
- Yes
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.43
- Highest tissue expression
- 2.6 nTPM
Expression across tissuesHPA
Tissue
- pituitary gland: 2.6 nTPM
- lymph node: 1.5 nTPM
- spleen: 1.2 nTPM
- hypothalamus: 1.1 nTPM
- bone marrow: 0.7 nTPM
- lung: 0.7 nTPM
Single-cell type
- extravillous trophoblasts: 967 nCPM
- endometrial secretory cells: 41 nCPM
- nk-cells: 25 nCPM
- migrating cytotrophoblasts: 17 nCPM
- epididymal efferent duct ciliated cells: 6.3 nCPM
- t-cells: 6.2 nCPM
Immune cell
- T-reg: 50 nTPM
- memory CD8 T-cell: 20 nTPM
- gdT-cell: 14 nTPM
- memory CD4 T-cell: 14 nTPM
- naive CD8 T-cell: 13 nTPM
- total PBMC: 7.8 nTPM
Brain region
- white matter: 0.9 nTPM
- hypothalamus: 0.7 nTPM
- pons: 0.6 nTPM
- hippocampal formation: 0.5 nTPM
- cerebral cortex: 0.4 nTPM
- medulla oblongata: 0.3 nTPM
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 1.88
- gnomAD pLI
- 0
- gnomAD missense Z
- -0.42
- DepMap mean gene effect
- -0.1
- DepMap dependency class
- selective
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 3% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
Cellular components
Protein domainsUniProt · Pfam · InterPro
KeywordsUniProt
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads LAIR2 as an antibody target. Whether an autoantibody or antibody against LAIR2 could matter depends on whether native LAIR2 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
LAIR2 is annotated as secreted, so native LAIR2 circulates and is directly accessible to antibodies. Secreted and cell-surface proteins are the autoantibody targets most likely to act like drugs, blocking or depleting the native protein.
Annotation status
The present source text does not explicitly label LAIR2 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...